Abstract
AbstractThis reflection paper presents a consolidated view of EFPIA on the need for principles for good practice in the generation and use of non-interventional studies (NIS), including overarching principles such as the registration of hypothesis evaluating treatment effect (HETE) studies. We first define NIS and the important adjacencies to clinical trials and relationship with real-world evidence (RWE). We then outline the principles for good practice with respect to appropriate research design, study protocol, fit-for-purpose variables and data quality, analytical methods, bias reduction, transparency in conduct and use, privacy management and ethics review. We conclude with recommendations for action for the research community to promote trust and credibility in the use of NIS.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference59 articles.
1. Flynn R, Plueschke K, Quinten C, Strassmann V, Duijnhoven RG, Gordillo-Marañon M, et al. Marketing authorization applications made to the European medicines agency in 2018–2019: what was the contribution of real-world evidence? Clin Pharmacol Ther. 2022;111(1):90–7.
2. Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The role of real-world evidence in FDA-approved new drug and biologics license applications. Clin Pharmacol Ther. 2022;111(1):135–44.
3. Office of Good Clinical Practice. Good clinical practice and clinical trials. In: U.S. Food and drug administration, editor. Multiple guidelines. Silver Spring, Maryland: U.S. Government Publishing Office. 2021.
4. European Medicines Agency. Good Clinical Practice Amsterdam, NL: European Medicines Agency. 2022. [summary of GCP guidance]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-clinical-practice.
5. Center for Drug Evaluation and Research. Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: draft guidance for industry. FDA-2021-D-1214. Draft ed. Silver Spring, Maryland: U.S. Food and Drug Administration; 2021. p. 12.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献